Semaglutide has emerged as the fourth pillar of diabetic kidney disease management, with clinical trial evidence showing it reduces kidney failure, cardiovascular death, and albuminuria across the spectrum of chronic kidney disease.
4th pillar of DKD therapySemaglutide now joins SGLT2 inhibitors, MRAs, and RAAS blockers as a foundational treatment for diabetic kidney disease based on major trial evidence
What the researchers found
The Evaluate Renal Function with Semaglutide Once Weekly trial demonstrated that semaglutide significantly reduced the risk of major kidney outcomes including kidney failure, death from kidney or cardiovascular causes, reduced albuminuria, and major cardiovascular events.
Based on this and supporting evidence, guidelines now position semaglutide as the fourth pillar of diabetic kidney disease therapy, complementing SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and renin-angiotensin-aldosterone system blockers. The review also notes emerging evidence for kidney-protective effects in people without diabetes, and metabolic benefits not achievable with the other three standard therapies.
Why it matters
Chronic kidney disease affects hundreds of millions worldwide and is a leading cause of death, especially in people with diabetes. Adding semaglutide as a fourth treatment pillar — with complementary mechanisms of action — represents a significant advance in kidney disease management and may help slow progression where existing three-drug combinations are insufficient.
How the study worked
This is a narrative review summarizing clinical evidence for semaglutide's kidney-protective effects. It draws primarily from the Evaluate Renal Function with Semaglutide Once Weekly trial and other clinical trial data, examining outcomes in individuals with and without type 2 diabetes across the spectrum of chronic kidney disease.
What this study cannot tell us
As a narrative review, this paper synthesizes existing evidence rather than generating new data. The evidence for kidney protection in people without diabetes is described as emerging and less established. Long-term outcomes beyond the trial follow-up periods are not yet known, and real-world effectiveness may differ from clinical trial results.
How to read the evidence
This review draws on evidence from the Evaluate Renal Function with Semaglutide Once Weekly trial, a large randomized controlled trial, along with other supporting clinical trial data. While the primary evidence base is strong, this paper is a narrative review rather than a systematic review or meta-analysis.
When this study was published
Published in 2025, this review incorporates the most recent trial data and guideline updates, making it highly current and reflective of the latest clinical practice standards.
The bigger picture
Semaglutide's recognition as kidney-protective represents the broader trend of GLP-1 drugs expanding far beyond blood sugar control. With proven benefits for the heart, kidneys, and metabolism, semaglutide is being repositioned as a foundational treatment for the interconnected cardio-kidney-metabolic disease spectrum — a paradigm shift in how these conditions are managed together.
Questions still open
- How effective is semaglutide for kidney protection in patients without type 2 diabetes, and will dedicated trials confirm the early signals?
- What is the optimal timing to add semaglutide to existing kidney-protective regimens — early in CKD or only after progression?
- How do the kidney-protective effects of semaglutide compare to those of tirzepatide and other newer GLP-1-based drugs?
Common questions
What are the four pillars of diabetic kidney disease treatment?
Can semaglutide help kidneys in people who don't have diabetes?
Read the original research
Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease.
World journal of nephrology, 14(4), 109457
Citation
Economos, Harry; MacIsaac, Richard J. (2025). Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease.. World journal of nephrology, 14(4), 109457. https://doi.org/10.5527/wjn.v14.i4.109457